Africa’s vast genetic diversity presents a unique opportunity for drug
research, yet global science has largely overlooked this potential, says
Professor Kelly Chibale of the University of Cape Town. Currently, only
3% of clinical trials are conducted on the continent. Chibale argues
for more testing in Africa, stating that it can yield drugs better
suited to varied genetic profiles. While he acknowledges that mistrust
rooted in colonial and apartheid histories would prevent many on the
continent from volunteering for trials, he believes that encouragement
from African health experts like himself can make a difference. Chibale
emphasizes the importance of local leadership in science, advocating for
African institutions to create conducive environments for clinical
trials. Successful drug innovation in Africa, he asserts, could drive
both health improvements and economic growth, while fostering scientific
independence. Chibale develops treatments for diseases affecting
African populations, like malaria and tuberculosis, at the H3D research
center he founded in 2011.
SOURCE: THE GUARDIAN